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ABSTRACT 
 
 
 
 
Genomic DNA was purified from Multiple Myeloma Cell Line JJN3, and BMF promoter 
region was PCR   amplified and cloned into pCR 2.1 TOPO vector using One Shot® 
Chemically Competent E. coli. After confirmation of the clone through polymerase chain 
reaction (PCR) and restriction analysis, BMF promoter (2.5 Kb) was released from TOPO 
vector and subcloned into pGL3 promoter vector. The resulting pGL3-BMF-promoter vector 
was further amplified for MaxiPrep preparation. This plasmid can be used to study the 
regulation of BMF promoter by various transcription factors including NF-κB family 
members. 
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Chapter I - Introduction 
What is Cancer? 
The living body is made up of millions of cells which, when normal, grow, divide, 
and die. In a young person, the cells normally divide faster, allowing growth to take 
place, whereas in an adult, the cells divide only to replace dying cells or to repair injuries. 
When these normal cells do not divide in a controlled fashion, cancer develops with an 
uncontrolled growth of cells. Unlike the normal cells, cancerous cells grow and give rise 
to new and abnormal cells. Cancer cells also have the potential to grow and metastasize 
to new tissues. These abnormalities are characteristics features of cancer cells. The 
fundamentally important material of the living cells is DNA, which controls the 
functionality of cells. Mutations, deletions, or damage in DNA can cause malignant 
transformation of cells, causing cancer. These cancer cells form a mass, which is called a 
tumor.  While many cancers such as lung, liver, breast, gastric, kidney and brain cancers 
form solid tumors, cancers relating to blood, such as leukemia, do not often form solid 
tumors (American Cancer Society, 2011). 
What is Multiple myeloma? 
Multiple myeloma is a cancer that develops due to malignant transformation of 
antibody-producing plasma cells.  Multiple myeloma is also known as plasma cell 
myeloma, plasmacytic myeloma, and myelomatosis and Kahler disease. Multiple 
myeloma is a neoplastic disorder distinguished by the multiplication of a clone of plasma 
cells that are derived from the B (B lymphocytes) cells (Kyle, 2003). Plasma cells form a 
malignant neoplasm, which accumulates in bone marrow, causing the destruction of the 
bone and bone marrow failure, leading to multiple myeloma, also known as bone marrow 
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cancer (Alsina & Bensinger, 2011).  It is a post-germinal center tumor formed by 
extensive somatic hyper mutation and antigen selection (Demchenko & Kuehl, May 
2010). Afro-Americans and males have a higher incidence of the disease, whose causes 
are unknown (Kyle, 2003; Angtuaco, 2004). It accounts for over 10% of the 
hematological and about 1% of the other types of malignancies. In 1873, J von Rustizky 
introduced the term multiple myeloma (Kyle, 2003). 
The B and T cells play an important role in fighting diseases and infections. When 
the B cells counter antigens causing infection, they mature into plasma cells within the 
germinal center (GC). These plasma cells then start producing antibodies or 
immunoglobulins to fight the infection. The long lived plasma cells migrate to the bone 
marrow, and within the bone marrow microenvironment plasma cells receive the survival 
signals to live for several days and keep producing antibodies. Under normal 
circumstances the plasma cells eventually die due to programmed apoptosis. However, 
due to a range of different mutations, plasma cells undergo malignant transformation and 
become resistant to apoptosis, leading to the development of multiple myeloma. The 
condition of myeloma begins with the plasma cells being abnormal; they then divide and 
make many copies, producing more and more abnormal cells. These abnormal cells are 
termed myeloma cells. The myeloma cells make the antibodies called M-proteins. Upon 
growing uncontrollably, the myeloma cells start to leave the bone marrow and form the 
tumor elsewhere by the process of metastasis. Moreover, by producing factors such as 
Receptor Activated Nuclear Factor of Kappa-B ligand (RANK-L), myeloma cells lead to 
bone lesions by promoting extensive osteoclastogenesis. At the late stage of the disease, 
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myeloma cells may even cause lesions in the skull, leading to the death of the patient 
(National Cancer Institute of the NIH, 2008). 
In Multiple myeloma, the abnormal growth of the plasma cells in the bone 
marrow leads to low count in blood cells causing anemia (loss of red blood cells), leading 
to fatigue and weakness. It also causes the lowering of the number of platelets, causing 
thrombocytopenia, which leads to increased bleeding. Leukopenia is also caused, which 
is a result of the lowering of white blood cells, which fight infections. Myeloma cells also 
obstruct the activity of the bone-forming and bone-destroying cells called osteoblasts and 
osteoclasts, respectively, and send signals by producing a substance to the osteoclasts to 
speed up the process of dissolving the bone. The osteoblasts do not receive a signal 
regarding formation of a new bone, which further leads to breaking of the older bone 
before a new one is substituted. In this diseased condition, the myeloma cells outnumber 
the normal plasma cells, so there will be no more antibodies made to fight infections 
(American Cancer Society, 2011). 
Currently multiple myeloma is considered an incurable disease. Although drugs 
such as Velcade® (Bortezomib) are currently in the clinic for the treatment of multiple 
myeloma, resistance to Velcade has been often reported, presumably due to the 
inefficiency of Velcade against the multiple myeloma progenitor cells. For all tumors it is 
well known that the tumor progenitor cells are the key cell types that form the tumors, 
and to completely eradicate the tumors, it is essential to target these progenitor cells and 
induce apoptosis in these cells. Therefore, it is essential to identify novel molecular 
targets which are absolutely essential for the survival and tumor formation by the 
Multiple myeloma tumor progenitor cells (Field-Smith, 2006). 
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What is MGUS? 
The antibodies made by the myeloma cells are less efficient in fighting infections 
as they are copies produced by one plasma cell. The condition is called monoclonal 
gammopathy. The condition of monoclonal gammopathy of undetermined significance 
(MGUS) may develop into multiple myeloma or some other related diseases. The 
production of excess amounts of a particular type of gamma globulins monoclonal leads 
to monoclonal gammopathy of undetermined significance (MGUS). It does not affect a 
person’s health but may eventually lead to amyloidosis and multiple myeloma. Some of 
the recent studies on genes of plasma cells of patients with MGUS revealed that these 
plasma cells have a genetic make-up that is much more similar to the myeloma plasma 
cells than the normal plasma cells, which suggests that these cells are malignant and 
divide rapidly. Compared to multiple myeloma, MGUS represents 10% or less of the 
mononuclear cells in the bone marrow, where the tumor cells continue to be stable but for 
a Progression to malignant multiple myeloma (American Cancer Society, 2011). 
Risk Factors for Multiple myeloma 
Changes in a person that increase the chances of acquiring a disease are termed 
risk factors. The risk of multiple myeloma increases with age and is more likely to 
develop in men than in women. It is more common among African Americans. Exposure 
to any amounts of radiations and workplace related exposures may also increase the 
chances of the disease. Plasma cell diseases like MGUS and Solitary Plasmacytoma will 
eventually develop multiple myeloma (American Cancer Society, 2012). 
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How is Multiple myeloma developed? 
The causes of most cases of multiple myeloma are still unknown. In spite of this, 
scientists have come to a point where they are able to recognize the specific changes in 
DNA that can cause the normal plasma cells to become abnormal cancer cells. Genes 
present in DNA that enhance cell division are potential oncogenes, and genes that reduce 
the process of cell division are called tumor suppressor genes. The disease can be caused 
by mutations in DNA that signal the oncogenes (like c-myc, N- ras, and K-ras) and the 
tumor suppressor genes (like p53) to turn on and off, respectively. In a normal human, 46 
chromosomes that control cell growth and other metabolic functions are present.  
However, in myeloma cells, some parts of chromosome 13 are missing; these deletions 
enable myeloma to be more antagonistic and resistant to any kind of treatment. Most 
myeloma patients have irregularly trans-located chromosomes, chromosomes with parts 
from other chromosomes (About Us: Multiple Myeloma Research Foundation, 2011).   
Recent studies revealed that the plasma cell tumors develop more when there is an 
excess production of the cytokine Interleukin-6 (IL-6) by certain cells in the bone marrow 
called dendritic cells, which stimulate the growth of normal plasma cells (American 
Cancer Society, 2011; About Us: Multiple Myeloma Research Foundation, 2011).  
Genetic abnormalities of multiple Myeloma 
Genetic abnormalities have shown to considerably impact most of the 
hematological malignancies. Recent research studies showed that several genetic factors 
have an influence in the development of multiple myeloma. Chromosomal aberrations 
like difference in structure and number constitute the genetic factors. Also, with the 
advancement of technology in mapping the human genome, scientists have discovered 
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various genes that are associated with early relapse of the disease (National Cancer 
Institute of the NIH, 2008). 
Chromosomal abnormalities of Multiple myeloma 
Chromosomal abnormalities have shown to play an important role in most of the 
hematologic malignancies. Recent studies by Debes-Marun et al. on the abnormal 
karyotypes of myeloma revealed that regular patterns of chromosomal changes were 
identified which classify the cytogenetics of the disease. It was also denoted that the most 
frequent chromosomal abnormalities are del(13) and 14q32, which are interconnected. 
The stage of the disease increases with the increase in the translocations involving the 
immunoglobulin heavy chain, IgH, which is normally 60-65% in intramedullary multiple 
myeloma and 70-80% in extramedullary multiple myeloma. 
The four major chromosomal partners involved in this translocation are: 11q13 
(cyclin D1), 6p21 (cyclin D3), 4p13 (FGFR3 and MMSET) (Malgeri, 2000) and 16q23 
(c-maf) (Bergsagel, 2001). A novel translocation was recently identified which is the 
t(4;14), (p16.3;q32), which causes the deregulation of FGFR3 and MMSET genes 
(Malgeri, 2000). 
What is NF-κB? 
Nuclear factor kappa-light-chain-enhancer of activated B cells, NF-κB, was first 
discovered by Ranjan Sen and David Baltimore (Gilmore, 1986; Singh, 1986; Sen, R 
1986), with the vital roles in the regulation of apoptosis, cell growth, and regulation of 
innate immunity and inflammatory responses (Zhuo, 2008). NF-κB also participates in 
the development and the activity of the central nervous system (Memet, 2006). 
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The NF-κB Family 
All of the NF-κB family proteins have a Rel Homology Domain (RHD) in their 
N- terminus. The NF-κB super family of transcription factors in mammals includes the 
following five transcription factors: p50 (NF-κB1/p105), p52 (NF-κB2/9100), RelA 
(p65), RelB and c-Rel. The RHD region is required for DNA-binding, dimerization, and 
interactions with the inhibitory κB proteins (IκBs) (TD Gilmore, 2006; Hoffmann A., 
2006; Moynagh, 2005) and also contains the nuclear localization sequence. NF-κB is a 
dimer of members of the Rel family of proteins (Grilli M, 1993; Kopp E, 1995). The first 
discovered NF-κB molecule was a heterodimer with the sub-units, p50 and p65 (Kopp, 
E., 1995; Verma, I.M., 1995). C-terminal transcriptional activation domains (TADs; 
Figure 1) exist in RelA, c-Rel, and RelB, enabling the activation of targeted gene 
expression (Karin, M., 2009).  On the contrary, p50 and p52 lack the C-terminal TADs 
that enable those homodimers to repress transcription unless they bind to a protein 
containing a TAD, such as RelA, c-Rel, or RelB or Bcl-3. The p50 and p52 family 
members are derived from large precursors, namely p105 and p100, respectively. The 
transcriptional activity of NF-κB is silenced by the interactions with inhibitory IκB 
proteins present in the cytoplasm (Hooper, 2010). 
A variety of homo- and heterodimers are formed by the sub-units p50, p52, c-Rel, 
RelA (p65), and RelB, in the mammalian NF-κB transcription complexes. The complexes 
bind to the κB-sites, which are the 9-10 base pair DNA regulatory sites to activate the 
specific target gene expression (Gilmore, 2006). The target gene specificity of these 
dimers is believed to have arisen from a number of factors: the specific NF-κB complexes 
in various cell types, the different protein-protein interactions, and posttranslational 
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modifications that NF-κB complexes undergo in different circumstances (Hoffmann, 
2006; Perkins, 2006). 
Inhibitory NF-κB proteins 
To date, there are seven known IκB (Inhibitors of NF-κB) molecules identified: 
IκBα, IκBβ, Bcl-3, IκBε, IκBϒ, and the precursor proteins, p100 and p105. The two 
precursor proteins are distinguished by the presence of ankyrin repeats, which contain 
multiple copies of a 30-33 amino acid sequence. (Hooper, 2010)  These ankyrin repeats 
interact with a region in the RHD of the NF-κB proteins. The IκB molecules have 
different affinities for individual NF-κB dimers. All the IκBs are similar in structure 
(Figure 2), but each has its own binding preferences and depends on the transcriptional 
regulation by NF-κB family members (Karin, 2009). The inhibitory IκB proteins regulate 
the activity of the NF-κB by interacting with them.  Each of the IκBs is regulated 
differently by phosphorylation and proteolysis, and they show differences in their tissue-
specific expression patterns.  From the structural views (Ghosh, 1999), it is also known 
that IκBα makes multiple contacts with NF-κB (Gilmore, 2006). 
Phosphorylation of IκBs results in their ubiquitination and subsequent degradation 
by the multicatalytic ATP-dependent 26S proteasome complex (Maniatis, 1999). 
Regulation of the NF-κB pathway is brought about by multiple post-translational 
modifications that control the activity of the core components of NF-κB signaling: the 
IκB kinase (IKK) complex. (Perkins, 2006) 
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Figure 1.  The NF-κB family - Diagram for different NF-κB members contains domains including 
ankyrin repeats (ANK), glycine-rich region (GRR), leucine zipper motif (LZ), Rel homology domain 
(RHD) and transcription activation domain (TAD).  Phosphorylation (P), acetylation (Ac), and 
ubiquitination (Ub) are the Post-translational modifications.  (Karin, 2009) 
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Figure 2. The IκB family diagram showing the IκB proteins with several ankyrin repeats (ANK) 
and Phosphorylation and ubiquitination at specific amino acid residues as indicated. The PEST 
domains are   indicated: Proline (P), glutamic acid (E), serine (S), and threonine (T). (Karin, 2009)  
 
 
In addition to the classical IκB family of proteins, the novel IκB-like proteins, 
BCL3 (B cell CLL/ lymphoma 3), IκBζ, and IκBNS, have a different type of regulation 
and serve different functions. BCL3 has been associated with cancer development, as it 
has the ability to regulate NF-κB activity, where it functions as a critical regulator of 
cyclin D1 transcription. IκBζ was recently identified with a weak homology to other 
family members. It associates with the p50 homodimers and may function in a similar 
manner to BCL3. IκBNS is also a unique IκB-like protein that is rapidly produced upon 
ligation of the T cell receptor (TCR) in thymocytes and plays an important role in 
negative selection of the T-cells (Rabek JP, 1998). 
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The IκB Kinase Complex 
The Inhibitors of NF-κB Kinase (IKK) complex consist of the sub-units IKKα, 
IKKβ, and IKKϒ, which is also called NEMO, NF-κB essential modulator. The IKK 
activation occurs upon activation of different types of signaling receptors, including the 
receptors of the TNFR family of receptors. The activated IKK complex phosphorylates 
the IκBα leading to polyubiquitination. The ubiqutinated IκBα is degraded by the 26S 
proteasome while exposing a nuclear localization signal on RelA and induces the nuclear 
translocation of the dimmers, RelA: p50. Among the three IKK subunits, IKKβ and IKKα 
are the catalytic subunits whereas IKKϒ is the regulatory subunit. Among IKKα and 
IKKβ, the latter is the major kinase for phosphorylating IκB-alpha, while in its absence, 
IKKα provides residual kinase activity towards IκB-alpha. Also, deletion of IKKα in the 
cells that express IKKβ has no effect on the classical IKK activity. An important and 
unique function of the IKKα is the activation of the alternative NF-κB pathway (Karin, 
2009). 
The NF-κB Signaling Pathways 
In the cytoplasm, NF-κB is present as a latent, inactive, IκB-bound complex. Two 
distinct pathways are known to activate the NF-κB. These two main pathways are called 
the canonical and non-canonical pathways. They are also termed the classical (p50- 
RelA) and alternative pathways (p52-RelB), respectively. While the classical pathway 
relies on the IKKα-dependent phosphorylation and degradation of IκB-alpha, the 
alternative pathway depends on NF-κB inducing kinase (NIK) and IKKα dependent 
phosphorylation and processing of p100 to p52 and subsequent nuclear translocation of 
p52-RelB heterodimers. Once in the nucleus, classical p50-RelA heterodimers or the 
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alternative RelB-p52 dimers regulate the expression of respective target genes (Karin, 
2009). 
Classical/Canonical Pathway 
The Classical Pathway is the well-studied NF-κB activation pathway and is 
activated by most stimuli, which mainly depends on the RelA: p50 heterodimers. The 
basis of this pathway is the activation of the trimeric IκB kinase (IKK) complex, which 
consists of IKKα and IKKβ and IKKγ/NEMO (Karin, 2000) and phosphorylation of IkBα 
leading to its degradation and nuclear translocation of p50-RelA heterodimers. Most 
inflammatory receptor signaling pathways such as the Tumor Necrosis Factor Receptor 
(TNFR) activation results in the recruitment of the IKK complex to the TNF Receptor 
(TNF-R) with the binding of the NEMO to a K63-ubiquitinated RIP1 (an adapter protein 
kinase essential for NF-κB activation by TNF-α) adaptor molecule on the TNF-R. 
Further, the activity of the IKKβ kinase is increased by two phosphorylations in its 
activation loop, resulting in the downstream events of NF-κB signaling (Herscovitch, 
2006). 
Upon being activated, IKKβ causes phosphorylation of two serine residues, Ser-
32 and Ser-36 on IκB-alpha leading to the complete degradation of the latter and nuclear 
translocation of p50-RelA heterodimers. Similar to TNFR signaling, in many other cases, 
ligand binds to a cell surface receptor (e.g., Toll-like receptors) and recruits adaptors (e.g. 
TRAFs and RIP) to the cytoplasmic domain of the receptor leading to subsequent 
recruitment of the IKK complex to the receptor proximal site where activation of the 
IKKβ occurs, which then phosphorylates IκB at two serine residues, leading to its K48 
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ubiquitination and thereby degradation by the proteasome. Now, NF- κB enters the 
nucleus (Figure 4) to turn on target genes (Gilmore, 2006). 
 
 
 
 
 
Figure 3. Post-translational modifications and structure of the IKK subunits (Perkins, N.D., 2006)  
 
 
 
Alternative/Non-Canonical Pathway 
The “non-canonical” NF-κB pathway depends on the activation of NIK and IKKα 
by a subset of the TNFR family of receptors such as CD40, BAFFF-R, lymphotoxin beta 
receptor, and so on. The action of NIK and IKKα results in the processing of the p100 
subunit to p52 (Bonizzi, 2004). In this pathway, p100/RelB is the inactive cytoplasmic 
NF-κB complex. The IKKα homodimer complex becomes activated by certain receptor 
signals, and phosphorylates the p100 at two C-terminal serine residues. Then, 
ubiquitination of p100 and its proteasomal processing to p52 results in the nuclear 
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translocation of a p52/RelB complex. While NIK and IKKα are absolutely essential for 
the activation of the alternative NF-κB pathway, IKKβ and IKKϒ are completely 
dispensible for this pathway. Moreover, unlike the classical pathway, the functions of the 
alternative pathway are not well understood. However, recent reports indicated that the 
alternative NF-κB pathway plays an important role in the organogenesis of secondary 
lymphoid organs (Karin, 2009; Figure 4). 
Interestingly, activation of the phosphatidylinositol-3-OH kinase (PI(3)K) 
pathway, in some cells, has been shown to lead to the phosphorylation of IKKα  at Thr-
23 and subsequent activation of the non-canonical pathway (Gustin, J.A., 2006). It can be 
inactivated by somatic mutations or deletions, and in some A20-deficient cells, re- 
expression of A20 leads to suppression of cell growth and NF-κB activity (Demchenko, 
2010). 
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Figure  4.  NF-κB signal transduction pathways (Canonical or Classical and Non-Canonical or 
Alternative Pathways). (Gilmore, 2006) 
 
 
 
 
NF-κB and Multiple myeloma 
Abnormal activation of NF-κB contributes to inherent drug resistance in 
numerous cancers, including multiple myeloma. The target genes of the NF-κB pathway 
vary depending on the type of inducer and the cells (Feinman, 2004). TRAF3 (TNF 
receptor-associated factor 3), which has been recognized as a regulator of the alternative 
NF-κB pathway, has never been involved in a malignant process. But a study (Keats, 
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2007) suggested that TRAF3 is frequently inactivated by mutations or deletions of this 
gene, and the loss of TRAF3 has been associated with constitutive activation of both 
classical and the alternative NF-κB pathways leading to drug resistance and growth 
advantage of multiple myeloma tumors. In this line, it can be suspected that TRAF3 
abnormalities may induce other malignancies as well. Another abnormality frequently 
found in most of the B-cell neoplasms is the loss of the function of the A20 protein, 
which is a key negative regulator of the classical pathway. 
NF-κB and Lymphoid Cancers 
The NF-κB family of transcription factors plays an important role in regulating 
gene expression essential for the generation of both innate and adaptive immune 
responses. While NF-κB promotes the proliferation, differentiation, and survival of 
lymphocytes, abnormal activity of NF-κB significantly adds to the pathogenesis of many 
lymphoid malignancies. (Nishikori, 2005) In some of the normal cells like B cells, T 
cells, Sertoli cells, and neurons, NF-κB is mainly located in the cytoplasm under resting 
conditions. However, in many cancer cells (including breast cancer, lymphoid cancers, 
and probably many others), NF-κB is active and is present in the nucleus due to 
mutations in the negative regulators of NF-κB or activating mutations in some of the 
upstream kinases. (Vallabhapurapu et al., 2009) Some of the human lymphoid cancer 
cells have mutations in the genes coding the Rel/NF-κB transcription factors. Most of the 
multiple myelomas have mutations in genes encoding NF-κB signaling regulatory 
proteins that lead to constitutive activation of NF-κB. It has been known that continuous 
nuclear Rel/NF-κB activity protects cancer cells from apoptosis and in some cases 
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enhances their growth, which makes it the reason why many of the current anti-tumor 
therapies prevent NF-κB activity to reduce tumor growth (Gilmore, 2006). 
The first relation between NF-κB and lymphoid malignancies was obtained from 
studies on the viral oncogene v-Rel, a homolog of the cellular c-Rel that causes leukemia 
and lymphoma (Gilmore, T.D., 1999). Subsequently, other studies revealed various 
genetic alterations involved in the NF-κB activity in B and T cell malignancies. In 
Hodgkin’s lymphoma, characterized by Hodgkin and Reed-Sternberg (HRS) cells, 
transcriptionally active forms of p50 homodimers complexed with BCL3 were detected 
(Mathas et al., 2005). Some studies suggest that elevated NF-κB in HRS cells is due to 
the activation of receptors such as CD30, CD40 and RANK (Thomas, 2004). 
Surprisingly, in large B cell lymphoma, CD40 forms complexes with c-Rel in the nucleus 
and enhances the expression of NF-κB target genes, including CD154, Blys/BAFF, and 
Bfl-1/A1, which indicates that the association between nuclear CD40 and c-Rel is 
important in the regulation of lymphoma cells (Zhou, 2007). 
While many studies involving NF-κB and tumorigenesis have been focused on the 
classical NF-κB pathway, the role of alternative NF-κB tumor cell survival and growth 
has been elusive. Interestingly, a recent report showed that RelB is required in radiation-
resistant stromal cells to promote T cell leukemia (dos Santos, 2008). Thus, in addition to 
its role in cancer cells, the alternative NF-κB signaling also plays a critical pro-oncogenic 
role in non-hematopoietic stromal cells by regulating their role with the leukemic cells 
(Karin, 2009). 
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BCl2 Modifying Factor (BMF) 
BMF, known as Bcl2-modifying factor, is a pro-apoptotic BH3-only member. It 
belongs to the Bcl2 family of apoptosis-related proteins. It contains only one BCL2 
homology domain 3 (BH3) and has been shown to function as an apoptosis activator. 
Also, it is associated with dynein light chain 2 and has been known to be an apoptotic 
“trigger” protein, which initiates programmed cell death in some epithelial cells when 
their attachment to the basal lamina is lost (Puthalakath, 2001). 
Bim (Bcl-2 interacting mediator of cell death) has an important biological role to 
play, compared to the other members of the BH3-only proteins, whereas little is known 
about Bmf, which is its closest relative. Bmf has a limited role to play while supporting 
Bim in some apoptotic processes. Bmf was originally discovered when performing the  
Y2H screen of a mouse embryonic cDNA library using Mcl1, although Bmf has lesser 
affinity to Mcl1 (Chen L, 2005), which recommends that amino acid residues outside the 
core of the BH3 domain are likely to add to identifying the binding specificities of Bmf in 
vivo. The presence of the functional BH3 domain was adequate for cell killing and 
binding and neutralization of Bcl-2-like molecules. Nonetheless, Bmf showed some 
degree of proapoptotic ability compared to other Bcl2-like molecules like Bim (Bcl-2 
interacting mediator of cell death; Pinon, 2009). 
Multiple isoforms of Bmf are found in the hematopoietic tissues, mostly in 
immature B and T cells (Labi, V, 2008). Two splice variants of BMF, Bmf II and Bmf 
III, were discovered in the healthy and malignant human B cells of patients with B cell 
lymphocytic leukemia. Remarkably, these variants lack the functional BH3 domain, and a 
different carboxyterminus was seen in Bmf III. Increased colony-forming potential was 
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seen in HeLa cells that express Bmf II and Bmf III, but Bmf I, the original form, was pro- 
apoptotic. (Morales AA, 2004)  In mouse, Bmf is located on chromosome 2 and in 
humans, on a syntenic region of chromosome 15 (Rodin SN, 2005). Bim and Bmf were 
hypothesized to be released from the cytoskeleton in response to the loss of adhesion 
and/or integrin signals preceding a distinct form of cell death, called anoikis, which is 
observed in fibroblasts, epithelial, or endothelial cells and prevents detached cells from 
colonizing elsewhere (Puthalakath, H., 1999). 
The Bmf gene expression is regulated by methylation-sensitive CpGs that are 
present in its promoter region, at the epigenetic level. Also, recent advances in research 
reveal that the protein expression in Bmf can be induced in melanoma and 
adenocarcinoma and in other cell lines of oral and esophageal cancers by the addition of 
new histone deacetylase inhibitors (Zhang, Y., 2006a). The Y2H screens also showed that 
Bmf is capable of binding to dyenin light chain 2, which is similar to the binding of Bim 
to the light chain 1. A highly conserved motif enables the binding of Bmf and Bim to the 
actin cytoskeleton and the microtubules, respectively, at their N-termini. It is believed 
that these proteins were circulated from the cytoskeleton in response to anoikis 
(Puthalakath, 1999). 
The presently known physiological role of Bmf is mainly from the gene-targeting 
experiments performed in mice. Importantly, studies from BMF-deficient mice indicated 
that BMF can function as a tumor suppressor owing to its role as a pro-apoptotic 
molecule. Moreover, lack of BMF impaired B-cell homeostasis and resulted in the B-cell 
restricted lymphadenopathy and gamma irradiation-induced thymic lymphomas (Labi, 
V., 2008a). It has also been suggested that apoptosis due to the loss of cytokines in the 
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bone marrow progenitor B cells and the regulation of the developmental splenic B-cells 
are controlled by Bmf and also Bim (Pinon, 2009). From earlier studies, it has been 
derived that Bmf has a function in the anoikis of epithelial cells (Puthalakath, 2002). 
BMF and Malignancies 
From studies (Pinon, 2009) conducted earlier in Myc-transgenic mice, it was clear 
that Bim acts as a tumor suppressor. In line with its role as a pro-apoptotic and tumor 
suppressor, in human Burkitt’s lymphoma, Bim was found to be silenced (Mestre- 
Escorihuela C, 2007). Similar to the role of Bim in oncogenesis, the role of Bmf as a 
tumor suppressor has been drawing attention.  It is important to note in this context that 
the loss of BMF enhances the gamma-irradiation-induced thymic lymphoma (Labi, V, 
2008a). 
Bmf and anti-tumor therapies 
Novel anti-tumor therapies aim to induce apoptosis in cancer/tumor cells. Bim, 
which is an effective initiator of apoptosis, was shown to be involved in some therapies 
as an important pro-apoptotic initiator. Induction of pro-apoptotic BH3-only proteins is 
therefore employed as a tool to induce apoptosis of tumor cells. Irrespective of the type of 
pro-apoptotic BH3-only proteins operating, they are important in the initiation of 
apoptosis owing to the fact that they can bind to the anti-apoptotic Bcl2 family members 
and neutralize them. This idea led to the development of imitative BH3 molecules that 
neutralize the anti-apoptotic Bcl2 members that are overexpressed in various cancers and 
initiate the release of proteins like Bmf (Labi.V, 2008b). These BH3 mimetics show an 
association with therapeutic compounds like tyrosine kinase inhibitors (TKIs), which 
include imatinib and erlotinib, though they lack efficacy for a single-compound. These 
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compounds have shown to be effective as specific compounds in the treatment of Chronic 
Myelogenous Leukemia (CML) and Non-Small Cell Lung Cancer (NSCLC) (Pinon, 
2009). 
In the novel clinical therapies, induction of apoptosis by Bmf has not been clearly 
defined. Although Bmf was upregulated in response to TKIs, its role in tumor apoptosis 
and its use in clinical therapies has been less studied. Bmf, along with Bim, was shown to 
be involved in the induction of apoptosis with respect to treatment of Acute Lymphoid 
Leukemia (ALL) with glucocorticoids (Ploner C, 2008) and arsenic oxide in the 
treatment of multiple myeloma (Morales, 2008). In most of the cancers, after treating the 
cells with HDACi, Bmf appeared to be upregulated (Zhang, 2006a). These HDACi’s 
belong to a class of capable anti-cancer agents, whose molecular mechanisms, in future, 
would lead to the invention of valuable therapeutics in combination with others, for 
treatment of the various types of cancers. Given the vast amount of information, Bmf, 
like Bim, will give the researchers a plethora of opportunities to develop the particular 
apparatus needed to treat malignancies (Pinon, 2009). 
Given the importance of BMF in the induction of tumor cell apoptosis, it is 
necessary to understand how BMF is regulated transcriptionally. In this study, I focused 
on how NF-κB might regulate BMF in multiple myeloma. 
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The Present Study and its Objective 
 
 
 
Current Objective: 
To clone a 2.5kb promoter region of BMF gene into luciferase reporter construct 
(pGL3-Promoter vector). 
The specific role of classical vs. alternative NF-κB in the survival and growth of 
multiple myeloma has been unclear. In particular, how the classical vs. alternative NF- 
κB pathways regulate pro-apoptotic genes such as BMF has not been clear. In order to 
study how these two pathways regulate the BMF expression, it is necessary to clone the 
BMF gene promoter into a reporter plasmid. 
Therefore, I aimed to clone a 2.5Kb promoter region of BMF gene into pGL3- 
promoter vector upstream of the luciferase gene. Prior to cloning the BMF promoter into 
the luciferase reporter construct, I first planned to clone it into the TOPO-T vector and 
eventually planned to subclone the BMF promoter into the pGL3-Promoter vector for 
performing luciferase reporter assays. 
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Chapter II – Materials and Methods 
 
 
 
Cell Line 
 
            Multiple myeloma cell line JJN3 was cultured in RPMI 1640 supplemented with 
10% fetal calf serum (FCS) and was cultured in a humidified atmosphere containing 5% 
CO2 at 37 °C. The cells were sub-cultured and were maintained as needed. 
Enzymes 
 
            Restriction endonucleases and enzymes used in cloning DNA were obtained from 
New England BioLabs. 
Isolation of genomic DNA and PCR amplification 
 
            Genomic DNA from the JJN-3 myeloma cell line was isolated by conventional 
phenol-chloroform method. Isolated DNA was seen on 2% agarose gel. Bmf promoter 
region (2.5 Kb) has been amplified by polymerase chain reaction (PCR) using the 
forward and reverse primers. The 40 μl reaction mixture contained 20 μl of mixture 
containing the Elongase enzyme, PCR buffer, 10 mM dNTP mixture and magnesium 
chloride, 2 μl each of the forward and reverse 2.5 Bmf primers, 1 μl autoclaved water, 
and 5 μl of 1:10 diluted JJN3 DNA.  The reaction mixture was incubated in a thermal 
cycler for initialization at 94°C for 5 min, 35 amplification cycles at 94°C for 30 seconds, 
1 min at 70°C Annealing temperature, followed by a final hold time of 5 min at 68°C. 
The PCR product was analyzed on 2% agarose gel, extracted, and purified by using 
QIAquick PCR Purification Kit (Qiagen). 
Cloning of Bmf promoter into pGL3 promoter vector 
 
            The cloning vector, pGL3 promoter vector is CIPped (Calf Intestinal Phosphatase, 
CIP- treated DNA fragments lack 5´ phosphoryl termini required by ligases and hence 
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cannot self-ligate). The purified 2.5 Kb Bmf promoter was ligated into pGL3 promoter 
vector (5010 bp), which contains the promoter-luc+ transcriptional unit, by using DNA 
ligase enzyme.  The reaction mixture (CIP, pGL3 vector DNA, Bmf DNA, Ligase) was 
incubated at 37°C for about 2 hours. 
 
 
 
 
 
 
 
 
Figure 5. pGL3 promoter vector with the restriction enzyme sites of BamHI, XbaI and SacI 
 
(Promega) 
 
 
 
The ligated mixture was transformed into E.coli DH5α competent cells (Promega, 
Madison, WI). Transformed (Heat shock) cells were selected from the LB (Luria-Bertani) 
agar plates (medium containing ampicillin, 100 μg/ml, and LB broth). The agar plates 
were incubated at 37°C overnight. Positive clones were identified by blue and white 
colony screening. The plasmid DNA was electrophoresed on 2% Agarose gel. 
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Cloning of Bmf gene (2.5 Kb) into TOPO TA (3.9 Kb) Vector 
 
            The recombinant plasmid pGL3 containing the Bmf promoter was digested with 
BamHI and XbaI restriction enzyme pair and double digested with KpnI and NheI. The 
pCR®2.1-TOPO® vector was also digested with the same enzymes. The restricted 
fragment as well as the double digested TOPO vector were run on 2% agarose gel, 
purified, and then ligated to the TOPO TA vector using DNA ligase. The ligated product 
was then transformed into One Shot® competent cells (TOPO TA cloning® of 
Invitrogen™). Positive clones were confirmed. 
Expression of Bmf promoter in One Shot® competent cells 
 
            A single transformed colony from LB agar plate (containing ampicillin) was 
picked up and inoculated into 50 ml of LB medium containing ampicillin (100 mg/ml). 
The medium was incubated overnight at 37°C in shaking incubator. 1 ml of overnight 
grown culture was then inoculated to 100 ml of the above mentioned LB medium and 
incubated at 37°C in shaking incubator. The culture was centrifuged at 6000 g for 10 min. 
The supernatant was discarded, the pellet was saved, and the plasmid DNA was eluted 
and purified by Qiagen Maxiprep Purification. The 6.4 Kb recombinant plasmid DNA 
was confirmed on 0.8% Agarose gel followed by staining with ethidium bromide and 
visualizing under the UV light in the Gel Doc System. 
Preparation of plasmids 
 
            pGL3 vector and pRL-TK Renilla vector encoding Firefly Luciferase and Renilla 
Luciferase, respectively were transformed into E.coli, isolated and purified using 
Maxiprep Plasmid Purification (Qiagen). Also, the DNA from the genes of interest, NF-
κB p52, p100 and RelB, was purified and further amplified for the purpose of 
transfection. 
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Cell line and culture medium 
 
 
            Human embryonic kidney cell line (293T) was cultured in Dulbecco's modified 
eagle medium (DMEM). The medium was complemented with 10% fetal calf serum 
(FCS), streptomycin at 100 μg/ml and penicillin at 100 U/ml. Cells were harvested at 
37°C in a 95% air and 5% CO2. Cells were split using trypsin/ethylenediaminetetraacetic 
acid (EDTA) medium as were maintained as needed. 
Transfection Protocol 
 
            Vector pGL3 alone, pGL3 with the Bmf insert (both contain the luciferase activity 
site) were taken in separate tubes with combinations of the amplified p52, p100, and 
RelB. The combinations taken for two wells each are pGL3 vector alone, pGL3-Bmf 
alone, pGL3 with RelB, pGL3-Bmf with RelB, pGL3 with RelB, and p52, and pGL3-
Bmf with RelB and p52. 
            For transfection, plain DMEM medium (without serum and antibiotics) was taken. 
200 μl of Lipofectamine® (Invitrogen™, Life Technologies, California) reagent was 
added to the above plasmid combinations taken in the respective tubes, and the tubes 
were incubated for 30 minutes at room temperature. The cells were sub-cultured and 
maintained as necessary. 
Luciferase Reporter assay 
 
            HEK-293T cells were transfected with the following plasmids in different 
combinations that express p52 (600 ng), and RelB (650 ng) as well as pGL3-Luc plasmid 
(200 ng), pGL3- BMG-luc plasmid (200 ng) and renilla luciferase plasmid (50ng) in the 
24-well plates. After incubation for about 24-36 hours, the cells were washed with 
phosphate-buffered saline (PBS) and then lysed in the passive lysis buffer supplied with 
the luciferase assay kit. Relative levels of luciferase were measured by measuring the 
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light units using a luciferase assay kit (Promega) with a luminometer as described in the 
manufacturer’s protocol. The data were expressed as relative light units (RLU) per well. 
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Chapter III - Results & Discussions 
 
Cloning of Bmf promoter into pGL3 vector 
            Although human BMF promoter may previously have been cloned into reporter 
plasmids by other investigators, for our convenience we intended to clone a 2.5 Kb 
proximal region of human BMF gene promoter from Myeloma cell lines into pGL3-
promoter vector. To this end, JJN-3 genomic DNA was isolated by Phenol-Chloroform 
method. Amplification of the Bmf gene promoter was performed by polymerase chain 
reaction using primers that would amplify a 2.5 Kb region of BMF promoter. The PCR 
cycles were approximately 36 at an annealing temperature of 70 ºC. The 2.5 Kb band of 
Bmf promoter obtained from the PCR was cut from the gel and purified by using 
QiaQuick gel extraction kit (Qiagen). 
 
 
 
 
 
 
 
                                              A      
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. “A” shows the 2.5 Kb band separated from the JJN3 genomic DNA by electrophoresis 
on a 2% agarose gel with “B”, the 10 Kb ladder. 
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The initial PCR reaction gave a smear in addition to the 2.5 Kb band for the BMF 
promoter. This could be due to a high concentration of genomic DNA. Therefore, I 
diluted the DNA 1:10 and 1:20, and the PCR has been performed again. As can be seen 
from Figure 7, 1:10 diluted genomic DNA gave a crisp band of 2.5 Kb size, which was 
then eluted from the agarose gel by QiaQuick gel extraction kit. The PCR primers used to 
amplify the 2.5Kb promoter region for BMF gene contained KpnI and NheI restriction 
sites to clone into the KpnI and NheI sites of the pGL3-Promoter Luciferase reporter 
vector. 
 
 
 
2.5Kb 
 
 
 
                                                    Marker 1:10 dil. 1:20 dil. 
 
                                                     10 Kb Water   Bmf Water Bmf 
 
 
 
 
 
Figure 7. PCR Amplified 2.5 Kb Bmf promoter on a 2 % agarose gel. 
 
 
 
 
            Prior to cloning into the pGL3-Promoter vector, the BMF gene promoter was 
cloned in pCR TOPO 2.1  vector (3.9 Kb) by quick ligation reaction at room temperature 
for 5 minutes. The ligated product was transformed in the One Shot® competent cells 
(Invitrogen, Life Technologies, California). Several colonies were screened for the 
presence of BMF promoter, and one of the positive clones was sequenced to confirm that 
the BMF promoter that we obtained has the correct sequence. 
            The 2.5 Kb BMF promoter fragment was released from the TOPO2.1 vector by 
KpnI and NheI digestion and ligated with pGL3 promoter vector that has also been 
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digested with KpnI and NheI. Prior to ligation, the pGL3 vector was treated with CIP to 
prevent vector self-ligation. Upon ligation, the pGL3 recombinant plasmid containing the 
2.5Kb BMF promoter fragment (pGL3-Bmf) was transformed into competent cells of E. 
coli DH5α. 
 
                                                      A       B   C 
 
 
 
 
                          5 Kb 
 
                          3 Kb 
 
                          2 Kb 
 
 
 
 
 
 
 
Figure 8. Release of 2.5Kb BMF promoter fragment from pGL3-BMF vector upon digesting with 
KpnI and NheI enzymes. “A” is the 10 Kb Ladder, “B” and “C” show the digestion fragments for 
clones 2 and 5, respectively. 
 
 
 
 
                                                       A     B           C   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. MiniPrep plasmid purification. A and B are Clones 2 & 5 respectively. C is the DNA 
ladder of 10 Kb length. 
 
 
 
            Positive clones were identified using blue and white screening. Several clones 
were screened by restriction digestion for the presence of the 2.5 Kb BMF promoter 
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fragment (Figure 8). Two different clones (Clones 2 and 5) were selected eventually for 
Maxiprep Plamid Purification (Qiagen) and confirmation by sequencing. 
            From the two clones obtained (clones #2 and #5), clone #5 was used to investigate 
how RelB and p52 may regulate the BMF promoter. However, initial studies involving 
luciferase assays did not produce convincing results about whether RelB and p52 regulate 
the BMF promoter. Further studies are required to conclude about the role of RelB and 
p52 in the regulation of BMF promoter. 
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Future Perspectives 
 
How tumors become resistant to apoptosis is an important question to address. While 
hyper-expression of anti-apoptotic genes has been extensively studied in various tumors, 
regulation of pro-apoptotic genes has not been clear. Especially, tumor-specific 
regulatory networks that achieve a finely balanced expression of pro- and anti-apoptotic 
genes seem to play an important role in tumor cell survival. To this end, regulation of 
BMF, a pro-apoptotic gene, is of great significance in the survival of not only multiple 
myeloma but also other types of tumors. Since NF-κB signaling is involved in various 
survival strategies that are operated in different tumors including multiple myeloma, it 
could be that BMF expression is under the regulation of NF-κB. Therefore, reporter 
studies such as luciferase assays to investigate BMF promoter regulation by NF-κB are 
an ideal experiment to perform. To this end, the pGL3-BMF-promoter-Luciferase 
reporter construct made in this study is of significant use for future studies to delineate 
how NF-κB and/or other transcription factors regulate the expression this important 
regulator of apoptosis in tumor cells. 
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